Abstract: A method and drug delivery system are provided for transdermally administering a psychedelic active agent to a subject to provide continuous microdose plasma levels of the active agent or a metabolite thereof during an extended drug delivery time period. The transdermal drug delivery system comprises a drug reservoir that houses a formulation containing the active agent, a combination of a solubilizer-type permeation enhancer and a plasticizer-type permeation enhancer, and a pH stabilizing agent. The pH stabilizing agent brings the pH of the formulation, at the system-skin interface, and/or within the skin as the active agent is transported across the skin from the skin surface to the bloodstream, to within 25% of the pKa of the active agent. Formulations and methods of use are also provided.

Abstract: A biodegradable composite may include a biodegradable plastic polymer having a biodegradability of from about 80 percent (%) to about 95% when measured according to a biodegradability test in accordance with an ASTM D6400-19 standard and a bio-derived fiber. A polymeric matrix of the biodegradable plastic polymer may have a tensile strength of from about 30 MPa to about 45 MPa and an elastic modulus of from about 2600 MPa to about 3600 MPa. The bio-derived fiber may have a tensile strength greater than the tensile strength of the polymeric matrix of the biodegradable plastic polymer and an elastic modulus greater than the elastic modulus of the polymeric matrix.

Abstract: A drug delivery system is provided for transdermally administering a psychedelic active agent to a subject to provide continuous microdose plasma levels of the active agent or a metabolite thereof during an extended drug delivery time period. The transdermal drug delivery system comprises a drug reservoir that houses a formulation containing the active agent, a combination of a solubilizer-type permeation enhancer and a plasticizer-type permeation enhancer, and a pH stabilizing agent. The pH stabilizing agent brings the pH of the formulation, at the system-skin interface, and/or within the skin as the active agent is transported across the skin from the skin surface to the bloodstream, to within 25% of the pKa of the active agent. Formulations and methods of use are also provided.